Navigation Links
Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
Date:4/16/2012

CINCINNATINew research at the University of Cincinnati (UC) suggests that kidney cancer growth depends on autophagy, a complex process that can provide cells with nutrients from intracellular sources. Researchers say in certain circumstances autophagy can protect tumor cells from chemotherapy, allowing them to survive for long periods of time in a hidden, dormant, metastatic state.

In this newly published data, researchers identify two distinct autophagy regulated pathways downstream from the von Hippel-Lindau tumor suppressor gene, or VHL. This specific tumor suppressor is lost in the majority of renal cell carcinomas.

UC researchers report these findings in the April 16, 2012, issue of Cancer Cell.

Maria Czyzyk-Krzeska, MD, PHD, corresponding author of the study, says the discoveries could guide researchers to more effective treatment approaches for kidney cancer, particularly metastatic disease, based on knowledge of these specific autophagic processes. UC collaborators in this study include David Plas, PhD, assistant professor of cancer and cell biology, and Jarek Meller, PhD, associate professor of environmental health.

"VHL has emerged as a master controller of access to intracellular nutrients through autophagy and to extracellular nutrients through formation of blood vessels. Our work shows that there are different autophagic programspro-and anti-oncogenic. Drugs that inhibit the final stages of autophagy non-specifically, such as derivatives of chloroquine, may not be as beneficial as hoped," explains Czyzyk-Krzeska, a professor of cancer and cell biology at the UC College of Medicine and researcher with the UC Cancer Institute.

She says the challenge is to understand the molecular mechanisms of these diverse autophagic pathways and identify targets that are specific to the pro-oncogenic pathway but not affecting tumor-suppressing pathways.

"Current drugs for metastatic kidney cancer target angiogenesisblocking the formation of blood vessels that feed the tumorbut they typically only increase survival by a matter of months," says Czyzyk-Krzeska. "We hope this new body of evidence can help pave a new path to more effective treatment options for this disease."

According to the American Cancer Society, incidence rates of kidney cancer are increasing steadily by 2 to 3 percent each year. The disease is curable when it is identified early and isolated to the kidney. Treatment options for metastatic disease are limited.


'/>"/>
Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Pollen.com Launches Features to Customize Allergy Information - Top Allergy Web Site Provides ZIP-specific Allergy Information and Diary to Track Symptoms
2. LifeScan Recalls Specific Lots of Consumer and Professional OneTouch(R) SureStep(R) Test Strips Due To Inaccurate Readings at High Levels
3. Latest quality and purity specifications for food ingredients help protect consumers
4. SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors
5. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
6. Even 9-Month-Olds Choose Gender-Specific Toys
7. Study of Williams syndrome patients reveals specific genes role in intelligence
8. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
9. Study: Specific PTSD symptoms related to anger and aggressiveness among Iraq/Afghanistan veterans
10. Aging and longevity tied to specific brain region in mice
11. Study shows patient-specific vaccines for metastatic melanoma may induce durable complete regression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: